Greg Pyszczymuka
Corporate Officer/Principal chez AYTU BIOPHARMA, INC.
Fortune : 64 661 $ au 30/04/2024
Profil
Greg Pyszczymuka is currently working as the Vice President-Commercial at Neos Therapeutics, Inc. since 2020.
He is also currently serving as the Chief Commercial Officer at Aytu Biopharma, Inc. In terms of education, Mr. Pyszczymuka holds an MBA from Argosy University and an undergraduate degree from Rutgers State University of New Jersey.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
0,41% | 31/03/2024 | 22 768 ( 0,41% ) | 64 661 $ | 30/04/2024 |
Postes actifs de Greg Pyszczymuka
| Sociétés | Poste | Début |
|---|---|---|
| AYTU BIOPHARMA, INC. | Corporate Officer/Principal | - |
| NEOS THERAPEUTICS, INC. | Corporate Officer/Principal | 01/11/2018 |
Formation de Greg Pyszczymuka
| Rutgers State University of New Jersey | Undergraduate Degree |
| Argosy University | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| AYTU BIOPHARMA, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Neos Therapeutics, Inc.
 Neos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Neos Therapeutics, Inc is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Its products are Adzenys XR-ODT (amphetamine), Cotempla XR-ODT (methylphenidate), and Adzenys-ER (amphetamine) extended-release oral suspension, all for the treatment of ADHD, are the first three approved products using the Company's extended-release technology platform. The firm manufactures and markets its generic version of the branded product Tussionex, an extended-release oral suspension of hydrocodone and chlorpheniramine for the relief of cough and upper respiratory symptoms of a cold. The company was founded by Darlene R. Ryan on November 30, 1994 and is headquartered in Grand Prairie, TX. | Health Technology |
